Last reviewed · How we verify
NCT01684098
A Phase II Clinical Study to Evaluate the Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor
Phase 2 trial testing Tc 99m EC20 in Recurrent or Metastatic Cancer in 40 participants. Completed in 1 August 2005.
Quick facts
| Lead sponsor | Endocyte |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | other |
| Enrollment | 40 |
| Start date | 1 August 2003 |
| Estimated completion | 1 August 2005 |
Drugs / interventions tested
- Tc 99m EC20 — full drug profile →
Conditions studied
- Recurrent or Metastatic Cancer — all drugs for Recurrent or Metastatic Cancer →
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
- Pancreas Cancer — all drugs for Pancreas Cancer →
- Bladder Cancer — all drugs for Bladder Cancer →
Sponsor
Endocyte — full company profile →
Who can join
18 and older, any sex, with Recurrent or Metastatic Cancer or Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The folate receptor is over-expressed on many types of cancer cells and new folate receptor targeted therapies are being developed to target cancer cells that over-express the folate receptor. As with other targeted therapies, it is important to develop diagnostic tests that will provide accurate information on folate receptor status and aid in selecting patients that may benefit from folate-targeted therapy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Targeting folate receptor alpha for cancer treatment.
Cheung A, Bax HJ, Josephs DH, Ilieva KM, et al · · 2016 · cited 298× · PMID 27248175 · DOI 10.18632/oncotarget.9651
Verify or expand the search:
- PubMed search for NCT01684098
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Endocyte trials
Trials by the same sponsor.
- NCT04597411 — Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer · Phase 1 · recruiting
- NCT03511664 — Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer · Phase 3 · completed
- NCT03042312 — Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy · Phase 2 · terminated
- NCT03011320 — An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery · Phase 1 · completed
- NCT01170650 — Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) · Phase 3 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01684098 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Endocyte
- Last refreshed: 20 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01684098.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing